Overview

Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate potential effects of valsartan on lipid subfractions and other parameters in lipid metabolism in patients with essential hypertension and metabolic syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Valsartan